Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|GCGR agonist therapies and DA signaling. While GCGR activators are widely employed for addressing type 2 diabetes, their emerging effects on reward circuits, specifically mediated by dopamine networks, are gaining considerable focus. This report details a brief assess… Read More